All adds:
Now 500 -$190 No more unless/until it turns.
09/24/2021 10:04:09 Bought 100 PAE @ 5.68 -568.00
Now 400 +$335 Not finding good forward estimates, but somebody is interested.
CFRA has it as a strong buy ( that's scary ) with no target.
09/24/2021 10:25:48 Bought 100 ARC @ 3.0899 -308.99
Now 900 +$1325
09/24/2021 15:08:07 Bought 100 ADIL @ 4.6 -460.00
Looks like nobody expects them to ever be profitable. Well, somebody must with a new 52 week high
today before pulling back.
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)))) ("Adial" or the "Company"), a clinical-stage
biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction
and related disorders, announces it has successfully enrolled 302 patients across 25 clinical sites and has
now closed enrollment for its ONWARD™ Phase 3 trial evaluating AD04 as a therapeutic agent for the
treatment of Alcohol Use Disorder (AUD) in persons with certain target genotypes related to the serotonin
transporter and receptor genes.
Tried to add to my 700 shares VTGN ( currently +$40 ) today, but I wanted too cheap. .
Someone always knows more, but I don't expect much until at least mid 2022. IF their drug works,
it could go big imho. Nasal spray for anxiety/depression.
From their last call:
The initiation of PALISADE-1 was a major milestone in the program. That study is proceeding as planned, with topline data
anticipated in mid-2022. We remain on track to initiate PALISADE-2, which will be a counterpart of PALISADE-1, later this
year, together with several other planned clinical studies we believe will be supportive of a potential U.S. New Drug
Application for PH94B if our PALISADE Phase 3 Program is successful. We have also made progress in our Phase 2A
clinical development program for PH94B, which is focused on additional anxiety disorders beyond SAD. We recently
received from the U.S. Food and Drug Administration notice that we may proceed with our proposed exploratory Phase 2A
clinical study of PH94B for treatment of adjustment disorder with anxiety. We expect to initiate that study in the U.S. before
year end," said Shawn Singh, Chief Executive Officer of VistaGen.
From their share sale last Dec.:
We believe that PH94B has the potential to be a novel, first-in-class neuroactive steroid nasal spray for use in a wide range of indications
involving anxiety or phobia. Designed to be self-administered in microgram doses, PH94B is designed to not require systemic uptake and
distribution to produce rapid-onset anti-anxiety effects. We are initially developing PH94B as a potential fast-acting, non-sedating, non-addictive,
new generation acute treatment of anxiety in adults with SAD. With its rapid-onset pharmacology, potential lack of systemic exposure and
favorable safety results, observed in clinical studies to date, we believe that PH94B also has potential to be developed as a novel treatment for a
broad range of anxiety disorders, including AjDA, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic and others.
Fair warning: biotechs can make you a lot of money, or eat you alive. Know your limitations, as it can happen before you can react. |
